• / Free eNewsletters & Magazine
  • / My Account

AES

The AES Corp AES

Last Price$13.12Day Change (%)-1.06%
Open Price$13.23Day Change ($)-0.14
Day Range13.10–13.2752-Week Range8.22–13.32

As of Mon 9/26/2016 5:28:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1

    Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1

  2. AES Energy Storage and RES Rank as Top Utility-Scale Energy Storage Systems Integrators in Navigant Research Assessment

    AES Energy Storage and RES Rank as Top Utility-Scale Energy Storage Systems Integrators in Navigant Research Assessment

  3. Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients

    Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients

  4. Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS

    Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS

  5. Fitch Affirms 2 National Collegiate Student Loan Trust Transactions

    Fitch Affirms 2 National Collegiate Student Loan Trust Transactions

  6. Fitch Takes Various Rating Actions on 3 National Collegiate Student Loan Trust Transactions

    Fitch Takes Various Rating Actions on 3 National Collegiate Student Loan Trust Transactions

  7. Chronic, Acute and Neuropathic Pain Market Report 2016 - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes - Research and Markets

    Chronic, Acute and Neuropathic Pain Market Report 2016 - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes - Research and Markets

  8. Medivir: Interim Results from Phase IIa Trial Evaluating Triple Combination Including Simeprevir Demonstrates High Level of Efficacy in HCV Patients

    Medivir: Interim Results from Phase IIa Trial Evaluating Triple Combination Including Simeprevir Demonstrates High Level of Efficacy in HCV Patients

  9. Positive Safety and Tolerability Profile of CER-001 Presented at the European Society of Cardiology (ESC) Congress 2016

    Positive Safety and Tolerability Profile of CER-001 Presented at the European Society of Cardiology (ESC) Congress 2016

  10. UPDATE: How NASA is working to take us deeper into space

    UPDATE: How NASA is working to take us deeper into space

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.